title: [Rationale of application of the drug Cytoflavin in complex treatment of patients with diabetic foot syndrome with mediacalcification arteries].
abstract: The study involved 60 patients with diabetic foot syndrome (DFS) with severe subcompensated diabetes type II. All patients were available mediacalcification foot and lower leg arteries of different severity. Depending on the treatment, all patients were divided into 2 groups by stratified randomization. The first group received basic therapy that is indicated for DFS which included antibiotics, vessels extending drugs neuroprotective and detoxification facilities. The second group of patients in addition to basic therapy received the drug cytoflavin 10 ml 0.9% NaCl 200 ml for 10 days, followed by transfer to the tablet form cytoflavin 2 tablets 2 times a day orally for 1 month. We noted a positive trend treat patients in addition to standard therapy received the drug cytoflavin, resulting in a marked neuroprotective, antihypoxant and antioxidant effects of the drug. Thus, the use of complex surgical treatment of patients with mixed form DFS cytoflavin reduces the severity of distal polyneuropathy, improves tissue oxygenation and restores the activity of antioxidant enzymes system, manifested a marked neuroprotective, anti-hypoxic and antioxidant effects of drugs and indications to justify its use in this condition.
authors.forename: I Ia
authors.initials: IIa
authors.lastname: Mikhaloĭko
authors.forename: R V
authors.initials: RV
authors.lastname: Sabadosh
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.forename: V D
authors.initials: VD
authors.lastname: Skripko
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage; D001158:Arteries / Q000473:pathology; D003131:Combined Modality Therapy; D003646:Debridement / Q000379:methods*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000378:metabolism; D017719:Diabetic Foot / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D004338:Drug Combinations; D016903:Drug Monitoring; D005260:Female; D005486:Flavin Mononucleotide / Q000008:administration & dosage*; D006801:Humans; D007290:Inosine Diphosphate / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage; D009536:Niacinamide / Q000008:administration & dosage*; D058729:Peripheral Arterial Disease / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology; D012720:Severity of Illness Index; D013386:Succinates / Q000008:administration & dosage*; D016896:Treatment Outcome; D061205:Vascular Calcification / Q000378:metabolism / Q000503:physiopathology; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000975:Antioxidants; D004338:Drug Combinations; D018696:Neuroprotective Agents; D013386:Succinates; D014665:Vasodilator Agents; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate